Wireless, miniaturised and distributed neural interfaces are emerging neurotechnologies. Although extensive research efforts contribute to their technological advancement, the need for real-time systems enabling simultaneous wireless information and power transfer toward distributed neural implants remains crucial. Here we present a complete wearable system including a software for real-time image capturing, processing and digital data transfer; an hardware for high radiofrequency generation and modulation via amplitude shift keying; and a 3-coil inductive link adapt to operate with multiple miniaturised receivers. The system operates in real-time with a maximum frame rate of 20 Hz, reconstructing each frame with a matrix of 32 × 32 pixels. The device generates a carrier frequency of 433.92 MHz. It transmits the highest power of 32 dBm with a data rate of 6 Mbps and a variable modulation index as low as 8 $\%$ , thus potentially enabling wireless communication with 1024 miniaturised and distributed intracortical microstimulators. The system is primarily conceived as an external wearable device for distributed cortical visual prosthesis covering a visual field of 20 $^{\circ }$ . At the same time, it is modular and versatile, being suitable for multiple applications requiring simultaneous wireless information and power transfer to large-scale neural interfaces.
Etoposide and methotrexate are widely used chemotherapy drugs in cancer treatment, targeting specific cellular processes crucial for DNA replication and cell division. Despite their efficacy, both drugs have significant adverse toxic effects due to the narrow therapeutic window, which can result in either over-exposure or insufficient exposure. Therefore, providing therapeutic drug monitoring is crucial to optimize pharmacotherapy outcomes to provide optimal dosage adjustment, and minimize adverse effects with personalized medicine and therapy. Conventional cytotoxic chemotherapies involve the combination of multiple antineoplastic drugs. Therefore, when developing sensors for therapeutic drug monitoring, it is important to account for the potential interactions between different drugs when they are simultaneously present in the blood of patients. However, the electrochemical interaction between etoposide and methotrexate has not been studied in multiplexed concentration monitoring. Therefore, our study aims to investigate their oxidation mechanism during simultaneous detection on the same sensor. We actually succeeded in demonstrating the simultaneous detections of the two drugs but, also, their mutual interference due to their oxidative cross-reactivity. To that aim, the reaction mechanisms between etoposide and methotrexate during their interaction on our sensor are presented in detail in this paper. A deep understanding of such an interaction is clearly crucial to calibrate the sensor in order to provide accurate and reliable detection of the two anti-cancer compounds.
Quantification of multiple drugs is of great importance and urgently needed in therapeutic drug monitoring (TDM) and personalized therapy. Especially, based on cyclic voltammograms (CV) obtained by electrochemical sensors, the use of artificial neural networks (ANNs) has been widely attempted in the accurate quantification of drug concentrations, enabling the development of point-of-care and potentially system-level wearable devices. However, most of the work only considers the accuracy of how the predicted value is close to the actual value, which does not consider whether the predicted drug concentration is underestimated. In practical drug quantification, potential toxicity due to overexposure with underestimated quantification can lead to endangering the patient's body. Therefore, avoiding underestimating the concentration of drugs based on existing quantification models is required and necessary to optimize the conventional loss function at the output stage of ANN. In this paper, a novel loss function based on Mean Squared Error (MSE), WeightedMSE, is proposed for avoiding underestimated quantification. It can be changed flexibly by adjusting parameters in order to adapt the acceptable overestimation range corresponding to the different types of drugs. A simulated dataset and a real dataset of Etoposide (ETO) and Methotrexate (MTX) are used as drug models, demonstrating that the proposed method can avoid underestimation in predicted values by over 98% in quantifying the concentration of multiple drugs and showing significant effectiveness for the development of point-of-care and wearable monitoring systems.
Electrochemical sensors play a pivotal role in advancing therapeutic drug monitoring (TDM) and personalized therapy. However, the insufficient selectivity of electrochemical sensors based on Cytochromes P450 poses a great need for innovative machine learning (ML) integrated with cyclic voltammograms (CV) obtained from electrochemical sensors and cyclic voltammetry to construct a fully-automated system for accomplishing the precise identification and quantification of multiple drugs in the patients' blood. An effective ML-based method is proposed in this paper with the adaptive transformation of Gaussian Mixture Model (GMM) algorithm for Gaussian feature extraction from the redox peak with peculiar characterisation and a novel Artificial Neural Network (ANN)-based model IdentQuantNet for the drug identification and quantification. The simulated dataset and measured dataset of Cyclophosphamide (CP) and Ifosfamide (IFO), proposed here as model drugs, are demonstrated to validate the efficacy of our proposed method. Our method can achieve the precision at 100 % for identification task and the Mean Absolute Error (MAE) at 4.88 and 6.67 for CP and IFO for the quantification task on the measured dataset.
Water scarcity increasingly challenges the supply of sufficient quantities of safe water for human consumption. On-site water reuse systems can contribute to mitigating the effects of water scarcity by closing water cycles locally. However, broader adoption of on-site water reuse is constrained by the high cost of water quality monitoring. This work demonstrates the successful design and validation of low-cost chlorine amperometric sensors for long-term monitoring using Prussian blue-coated screen-printed carbon electrodes. The study is relevant for practice, as testing was conducted in a water reuse system treating real greywater and municipal wastewater. The sensors achieved a relatively stable sensitivity of 8.55 ± 1.19 μA/(ppm⋅cm2) for hypochlorous acid after a 3-day stabilization period and maintained a sensitivity of 3.72 μA/(ppm⋅cm2) after 1 month. The sensors exhibited a linear dynamic range from 0.3 to 5 ppm for hypochlorous acid (R2 > 0.95). This study highlights the potential of Prussian blue-coated sensors as a practical solution for continuous chlorine monitoring in on-site water reuse applications. The findings encourage further research to improve durability and scalability to optimise the sensors for applications where low-cost sensing solutions are needed without personnel on-site for regular sensor maintenance and calibration.